However, in terms of antitumor immunity, low-risk patients scored significantly higher in HLA signature, CD8+ effector T cells, tumor antigen presentation, and interferon-gamma response than those high-risk ones (Figures 9C, F). The gene discussed is CD8A; the disease is neoplasm.